[go: up one dir, main page]

WO2001066689A3 - Nouveaux acides nucleiques et polypeptides - Google Patents

Nouveaux acides nucleiques et polypeptides Download PDF

Info

Publication number
WO2001066689A3
WO2001066689A3 PCT/US2001/004942 US0104942W WO0166689A3 WO 2001066689 A3 WO2001066689 A3 WO 2001066689A3 US 0104942 W US0104942 W US 0104942W WO 0166689 A3 WO0166689 A3 WO 0166689A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypeptides
novel nucleic
novel
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/004942
Other languages
English (en)
Other versions
WO2001066689A2 (fr
Inventor
Y Tom Tang
Chenghua Liu
Vinod Asundi
Chongjun Xu
Tom Wehrman
Feiyan Ren
Yunqing Ma
Ping Zhou
Qing A Zhao
Yonghong Yang
Radoje T Drmanac
Jie Zhang
Rui-Hong Chen
Aidong J Xue
Jian-Rui Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyseq Inc
Original Assignee
Hyseq Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc filed Critical Hyseq Inc
Priority to AU2001245280A priority Critical patent/AU2001245280A1/en
Priority to US10/221,278 priority patent/US20040034208A1/en
Priority to CA002402293A priority patent/CA2402293A1/fr
Priority to EP01918174A priority patent/EP1261743A2/fr
Publication of WO2001066689A2 publication Critical patent/WO2001066689A2/fr
Publication of WO2001066689A3 publication Critical patent/WO2001066689A3/fr
Anticipated expiration legal-status Critical
Priority to US10/291,172 priority patent/US20030228584A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à de nouveaux acides nucléiques, à de nouvelles séquences de polypeptides codées par ces acides nucléiques et à des utilisations de ceux-ci.
PCT/US2001/004942 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides Ceased WO2001066689A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001245280A AU2001245280A1 (en) 2000-03-07 2001-03-05 Novel nucleic acids and polypeptides
US10/221,278 US20040034208A1 (en) 2001-03-05 2001-03-05 Novel nucleic acids and polypeptides
CA002402293A CA2402293A1 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides
EP01918174A EP1261743A2 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides
US10/291,172 US20030228584A1 (en) 2000-03-07 2002-11-08 Novel nucleic acids and polypeptides

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US51970500A 2000-03-07 2000-03-07
US09/519,705 2000-03-07
US57445400A 2000-05-19 2000-05-19
US09/574,454 2000-05-19
US59619300A 2000-06-17 2000-06-17
US09/596,193 2000-06-17
US61684700A 2000-07-14 2000-07-14
US09/616,847 2000-07-14
US66536300A 2000-09-19 2000-09-19
US09/665,363 2000-09-19
US69326700A 2000-10-20 2000-10-20
US09/693,267 2000-10-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/291,172 Continuation-In-Part US20030228584A1 (en) 2000-03-07 2002-11-08 Novel nucleic acids and polypeptides

Publications (2)

Publication Number Publication Date
WO2001066689A2 WO2001066689A2 (fr) 2001-09-13
WO2001066689A3 true WO2001066689A3 (fr) 2002-05-30

Family

ID=27560092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004942 Ceased WO2001066689A2 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides

Country Status (4)

Country Link
EP (1) EP1261743A2 (fr)
AU (1) AU2001245280A1 (fr)
CA (1) CA2402293A1 (fr)
WO (1) WO2001066689A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7425612B2 (en) 2002-06-06 2008-09-16 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953682B2 (en) 2000-02-10 2005-10-11 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor
AU2002228003A1 (en) * 2000-12-14 2002-06-24 Bayer Aktiengesellschaft Regulation of human uridine kinase
US20040072997A1 (en) * 2000-12-20 2004-04-15 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
EP2153843B1 (fr) 2001-09-18 2012-08-15 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic d'une tumeur
AU2003226444A1 (en) * 2002-04-01 2003-10-13 Asahi Kasei Pharma Corporation Vascularization controlling gene
WO2005117986A2 (fr) 2004-06-01 2005-12-15 Genentech, Inc. Conjugues de medicaments anticorps et procedes correspondants
US20060110731A1 (en) * 2002-05-15 2006-05-25 Reinhard Ebner Cancer-linked gene as target for chemotherapy
GB0215295D0 (en) * 2002-07-02 2002-08-14 Inpharmatica Ltd Proteins
EP1611239A1 (fr) * 2003-03-26 2006-01-04 Novartis AG Proteines activateurs d'elements de reponse amp cyclique et utilisations correspondantes
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
GB0320878D0 (en) * 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
EP2267154A1 (fr) 2003-10-23 2010-12-29 Illumigen Biosciences, Inc. Oligoadenylate synthétase
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006097335A1 (fr) * 2005-03-18 2006-09-21 Universität Zürich Nouvel element de la voie de signalisation wg/wnt
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
WO2009093246A2 (fr) * 2008-01-22 2009-07-30 Compugen Ltd. Nouveau peptide dérivé de clusterine
WO2011031870A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugués médicamenteux ciblés à visée extracellulaire
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Ulc Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
MX2012011901A (es) 2010-04-15 2012-11-29 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas.
CN107335062B (zh) 2010-06-08 2021-09-24 基因泰克公司 半胱氨酸改造的抗体和偶联物
CN103429254A (zh) * 2010-10-11 2013-12-04 南加利福尼亚大学 分泌的热休克蛋白-90α（Hsp90α）片段作为用于对抗一系列人类实体肿瘤的单克隆抗体药物的疫苗或表位或小分子药物的靶点
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
CA2833212C (fr) 2011-05-12 2020-06-09 Genentech, Inc. Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre
CA2850371C (fr) 2011-10-14 2020-06-30 Spirogen Sarl Pyrrolobenzodiazepines et conjugues associes
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
HUE039329T2 (hu) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
SMT201900017T1 (it) 2012-10-12 2019-02-28 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
WO2014140174A1 (fr) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
CA2904044C (fr) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines et leurs conjugues
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
CR20160271A (es) 2013-12-16 2016-12-02 Genentech Inc Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
CN106714844B (zh) 2014-09-12 2022-08-05 基因泰克公司 蒽环类二硫化物中间体、抗体-药物缀合物和方法
MA40575A (fr) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
MX379396B (es) 2014-11-25 2025-03-11 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
EP3496763A1 (fr) 2016-08-11 2019-06-19 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11260101B2 (en) * 2017-02-28 2022-03-01 Jinan University Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
WO2018192944A1 (fr) 2017-04-18 2018-10-25 Medimmune Limited Conjugués de pyrrolobenzodiazépine
CA3057748A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polytherapie avec un conjugue anticorps anti-axl-medicament
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
BR112020004307A2 (pt) 2017-09-20 2020-11-10 Ph Pharma Co., Ltd. análogos de tailanestatina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7520870B2 (ja) 2019-03-15 2024-07-23 メドイミューン・リミテッド がんの治療における使用のための、アゼチドベンゾジアゼピン二量体及びこれを含む複合体
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CA3236930A1 (fr) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Conjugaison specifique d'un anticorps
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 6 February 1997 (1997-02-06), WANG ET AL.: "Direct submission", XP002908399, Database accession no. U51114 *
WATSON ET AL.: "The science used in recombinant DNA industry. Recombinant DNA; A short course", 1983, W.H. FREEMAN AND COMPANY, NEW YORK, XP002945246 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7425612B2 (en) 2002-06-06 2008-09-16 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
US7705141B2 (en) 2002-06-06 2010-04-27 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
US7847065B2 (en) 2002-06-06 2010-12-07 Oncotherapy Science, Inc. CXADRL1 polypeptides relating to human cancers
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Also Published As

Publication number Publication date
AU2001245280A1 (en) 2001-09-17
WO2001066689A2 (fr) 2001-09-13
CA2402293A1 (fr) 2001-09-13
EP1261743A2 (fr) 2002-12-04

Similar Documents

Publication Publication Date Title
WO2001075067A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057188A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002031111A3 (fr) Acides nucleiques et polypeptides
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003054152A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003025148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002070539A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003023013A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002081731A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
WO2004009834A3 (fr) Nouveaux acides nucleiques et polypeptides secretes
WO2004080148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003029271A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO2003080795A3 (fr) Nouveaux acides nucléiques et polypeptides sécrétés
WO2005049806A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001002571A3 (fr) Nouvel antagoniste du recepteur d'interleukin-1 et ses utilisations
WO2001075068A3 (fr) Proteines secretee et polynucleotides codant pour ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2402293

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001918174

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10291172

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001918174

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10221278

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001918174

Country of ref document: EP